C WorldWide Group Holding A S purchased a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 100,000 shares of the biotechnology company’s stock, valued at approximately $1,615,000. C WorldWide Group Holding A S owned 0.18% of Heron Therapeutics at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of HRTX. Legal & General Group Plc raised its stake in Heron Therapeutics by 13.9% in the 1st quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 1,098 shares during the period. Quantbot Technologies LP raised its stake in Heron Therapeutics by 2,619.6% in the 2nd quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 12,024 shares during the period. HighTower Advisors LLC raised its stake in Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 1,700 shares during the period. Tudor Investment Corp ET AL bought a new stake in Heron Therapeutics in the 1st quarter valued at $253,000. Finally, Voya Investment Management LLC raised its stake in Heron Therapeutics by 44.4% in the 2nd quarter. Voya Investment Management LLC now owns 20,377 shares of the biotechnology company’s stock valued at $282,000 after acquiring an additional 6,267 shares during the period.
ILLEGAL ACTIVITY WARNING: “100,000 Shares in Heron Therapeutics, Inc. (HRTX) Purchased by C WorldWide Group Holding A S” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://ledgergazette.com/2017/11/13/100000-shares-in-heron-therapeutics-inc-hrtx-purchased-by-c-worldwide-group-holding-a-s.html.
A number of equities research analysts recently weighed in on the company. Mizuho restated a “buy” rating and issued a $28.00 price target on shares of Heron Therapeutics in a research note on Tuesday, November 7th. Cantor Fitzgerald set a $31.00 price target on Heron Therapeutics and gave the company a “buy” rating in a research note on Friday, October 20th. Cowen and Company restated a “buy” rating and issued a $40.00 price target on shares of Heron Therapeutics in a research note on Monday, November 6th. BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Finally, Aegis restated a “buy” rating and issued a $33.00 price target on shares of Heron Therapeutics in a research note on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. Heron Therapeutics presently has an average rating of “Buy” and an average price target of $28.36.
Shares of Heron Therapeutics, Inc. (HRTX) traded down $1.00 during midday trading on Monday, reaching $16.35. The company’s stock had a trading volume of 2,357,100 shares, compared to its average volume of 817,824. Heron Therapeutics, Inc. has a 52-week low of $12.21 and a 52-week high of $20.85. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62.
Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.10. The company had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. equities analysts forecast that Heron Therapeutics, Inc. will post -3.42 earnings per share for the current fiscal year.
Heron Therapeutics Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX).
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.